FDA unauthorizes use of Regeneron, Eli Lilly antibody treatments; new version of omicron reported Live COVID ١٩ updates

أكثر من ٣ سنوات فى USA Today

The FDA said the two treatments are unlikely to work against the omicron variant, which makes up 99% of U.S. cases. Latest COVID-19 news.     

ذكر فى هذا الخبر
شارك الخبر على